## **REMARKS**

Claims 17-31 are pending in the present application.

The Examiner has required election in the present application between:

Group I, claims 17, 18, and 26-30, drawn to a method of treatment or prophylaxis comprising using an antibody to modulate TWEAK;

Group II, claims 17, 18, and 26-30, drawn to a method of treatment or prophylaxis comprising using an antibody to modulate the TWEAK receptor;

Group III, claims 17, 18, and 26-30, drawn to a method of treatment or prophylaxis comprising using an antibody to modulate both TWEAK and the TWEAK receptor;

Group IV, claims 17, 19-21, and 26-30, drawn to a method of treatment or prophylaxis comprising using an antisense RNA or an siRNA to modulate TWEAK;

Group V, claims 17, 19-21, and 26-30, drawn to a method of treatment or prophylaxis comprising using an antisense RNA or an siRNA to modulate the TWEAK receptor;

Group VI, claims 17, 19-21, and 26-30, drawn to a method of treatment or prophylaxis comprising using an antisense RNA or an siRNA to modulate TWEAK and the TWEAK receptor;

Group VII, claims 17, 22, and 26-30, drawn to a method of treatment or prophylaxis comprising using a ribozyme to modulate TWEAK;

Group VIII, claims 17, 23, 24, and 26-30, drawn to a method of treatment or prophylaxis comprising using a TWEAK antagonist;

Application No.: 10/589,823 Docket No.: 4266-0126PUS1

Group IX, claims 17 and 25-30, drawn to a method of treatment or prophylaxis comprising using a soluble part of the TWEAK receptor; and

Group X, claim 31, drawn to a method for identifying a substance.

For the purpose of examination of the present application, Applicants elect, without traverse, Group IV, claims 17, 19-21, and 26-30.

The Examiner has further required an election in the present application to a specific neurological disease or condition in claims 27-29.

For the purpose of examination of the present application, Applicants elect Species "stroke", without traverse.

All of the above elected claims from the restriction requirement, claims 17, 19-21, and 26-30, are directed to the elected species.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Thomas J. Siepmann, Ph.D., Registration No 57,374, at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

Application No.: 10/589,823 Docket No.: 4266-0126PUS1

Attached is a Petition for Extension of Time.

Attached hereto is the fee transmittal listing the required fees.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated:

AUG 2 8 2008

Respectfully submitted,

Marc S. Weiner

Registration No.: 32,181

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant